ArticleBMC pharmacology & toxicology2026
Acetylshikonin alleviates gouty arthritis by increasing sirtuin1 expression and promoting lymphatic drainage.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGouty arthritis (GA) is a common and painful inflammatory joint disease. Acetylshikonin (Askn), a major bioactive compound extracted from the traditional Chinese medicine Arnebia euchroma, has an unknown therapeutic potential and mechanism of action against GA. This study aimed to investigate the effects and underlying mechanisms of Askn in a mouse model of GA.
methodsA GA model was established in 6- to 8-week-old male mice by injecting a 3% monosodium urate (MSU) crystal suspension into the hind paw metatarsophalangeal joint. The mice were randomly divided into three groups: the healthy control group, the GA model group, and the Askn-treated group (30 mg/kg, i.p.). Each group consisted of n = 10 mice. The primary endpoint was the degree of paw swelling, which was assessed by a Vernier calliper. Secondary assessments included liver/kidney toxicity (H&E staining and ultrasound), inflammatory factor expression (qRT‒PCR and immunofluorescence), and lymphatic drainage (ICG‒NIR imaging).
resultsPaw swelling was significantly lower in Askn-treated mice than in the GA model group. Askn treatment did not induce hepatotoxicity or nephrotoxicity. A significant improvement in the inflammatory pathological condition of the synovial tissues and surrounding soft tissues at the metatarsophalangeal joint was observed in Askn-treated mice. The mRNA expression of IL-1β, TNF-α, IL-6, and iNOS markedly decreased following Askn treatment. Furthermore, Askn significantly enhanced lymphatic drainage, as indicated by ICG signal intensity, and modulated the SIRT1/NLRP3 pathway.
conclusionAskn alleviates GA symptoms by enhancing lymphatic drainage and upregulating SIRT1 expression, which subsequently inhibits NLRP3-mediated inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.